---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056848"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:10:07.432116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma reports Q1 2024 net loss $12.3M, cash $41M into Q1 2025

## Summary
- Collaboration revenue $1.7M vs $0.2M YoY; net loss $0.25/share vs $0.29.
- Cash and equivalents $41.0M at March 31, expected to fund operations into Q1 2025.
- CUE-101 abstract accepted for oral presentation at ASCO 2024; FDA meeting on registrational path.
- Preclinical CUE-401 (with Ono) and new CUE-500 series for autoimmune/inflammatory diseases.
- R&D expenses $10.2M, G&A $4.2M; net loss $12.3M for the quarter.

## SEC filing metadata
- accession: 0000950170-24-056848
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/0000950170-24-056848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/cue-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056848
- JSON: https://secwatch.observer/filing/0000950170-24-056848.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056848.txt

## Key facts
- Earnings Releases
  Cue Biopharma, Inc. reported first quarter 2024 results: revenue $1.7 million, net income Net loss $(12.3) million, EPS $(0.25) per share.
  - Period: first quarter 2024
  - Revenue: $1.7 million
  - Net income: Net loss $(12.3) million
  - EPS: $(0.25) per share
  - Result: reported results
  source text: disease positions us well to potentially deliver value creation for our shareholders.” First Quarter 2024 Financial Results The Company reported collaboration revenue of $1.7 million and $0.2 million for the three months ended March 31, 2024 and 2023, respectively. The increase was due to revenue earned from our Collaboration and Option Agreement with Ono
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017024056848/0000950170-24-056848-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.